On Tuesday, November 13, Sean Parker, founder and chairman of the Parker Institute for Cancer Immunotherapy, will discuss the latest advances in cancer detection and treatment, and challenges cancer presents during The Washington Post’s “Chasing Cancer” summit.

Parker will join other leading cancer experts including FDA Commissioner Dr. Scott Gottlieb to discuss the latest developments in precision medicine aimed at treating cancer, how HPV-related cancers are on the rise in the U.S., and, examine the cost of cancer care and treatment and proposed solutions on how to ease the burden on those impacted by the disease.

Speakers include:

  • Sean Parker, Founder and Chairman of the Parker Institute for Cancer Immunotherapy
  • Dr. Scott Gottlieb, Commissioner, Food and Drug Administration
  • Norman “Ned” E. Sharpless, M.D., Director, National Cancer Institute
  • Maura L. Gillison, M.D.,  Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 
  • Steve Hendrix, Feature Writer, The Washington Post
  • Dr. Ezekiel J. Emanuel, M.D., Vice Provost for Global Initiatives and Chair, Department of Medical Ethics and Health Policy, University of Pennsylvania
  • Douglas R. Lowy, M.D., Deputy Director, National Cancer Institute and Chief of the Laboratory of Cellular Oncology, National Institutes of Health
  • Peter B. Bach, MD,  Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
  • Jennifer Bryant, Senior Vice President for Policy and Research, PhRMA
  • Akila Viswanathan, MD,  Executive Vice Chair, Johns Hopkins Radiation Oncology and Molecular Radiation Sciences 

More speakers to be announced.

This event is open to press and will be streamed on The Post’s site at wapo.st/chasingcancer2018 Media who wish to cover must RSVP.

Event Details

Tuesday, November 13, 2018

8:30 AM - 10:30 AM (Doors open at 8:00 AM)

The Washington Post Live Center

1301 K St NW

Washington, D.C. 20071

The presenting sponsor of “Chasing Cancer” is AstraZeneca, and with support from Johns Hopkins Kimmel Cancer Center.